2,636 Icelandic genomes pinpoint risk for Alzheimers, other diseases

'Dialogue' by Anna Leoniak and Fiann Paul, a 2008 Reykjavk Arts Festival exhibit featuring photographs of children from Icelandic rural areas.

An Icelandic genetics firm has sequenced the genomes of 2,636 of its countrymen and women, finding genetic markers for a variety of diseases, as well as a new timeline forthe paternal ancestor of all humans.

Iceland is, in many ways, perfectly suited to being a genetic case study. It has a small population with limited genetic diversity, a result of the population descending from a small number of settlersbetween 8 and 20 thousand, who arrived just 1100 years ago.It also has an unusually well-documented genealogical history, with informationsometimes stretching all the way back to the initial settlementof the country. Combined with excellent medical records, it'sa veritable treasure trove for genetic researchers.

The researchers at genetics firm deCODE compared the complete genomes of participants with historical and medical records, publishing their findings in a series of four papers in Nature Geneticslast Wednesday. The wealth of data allowed them to track down genetic mutations that are related to a number ofdiseases, some of them rare. Although few diseases are caused by a single genetic mutation, a combination of mutations can increase the risk for certain diseases. Having access to a large genetic sample with corresponding medical data can help to pinpoint certain risk-increasing mutations.

Among their headline findings was the identification of the gene ABCA7 as a risk factor for Alzheimers disease. Although previous research had established that a gene in this region was involved in Alzheimers, this result delivers a new level of precision. The researchers replicated their results in further groups in Europe and the United States.

Also identified was a genetic mutation that causes early-onset atrial fibrillation, a heart condition causing an irregular and often very fast heart rate. Its the most common cardiac arrhythmia condition, and its considered early-onset if its diagnosed before the age of 60. The researchers found eight Icelanders diagnosed with the condition, all carrying a mutation inthe same gene,MYL4.

The studiesalso turned up a gene with an unusual pattern of inheritance. Itcauses increased levels of thyroid stimulation when its passed down from the mother, but decreased levels when inherited from the father.

Genetic research in mice often involves knocking out or switching off a particular gene to explore the effects. However, mouse genetics arent a perfect approximation of human genetics. Obviously, doing this in humans presents all sorts of ethical problems, but a population such as Iceland provides the perfect natural laboratory to explore how knockouts affect human health.

The data showed that eight percent of people in Iceland have the equivalent of a knockout, one gene that isnt working. This provides an opportunity to look at the data in a different way: rather than only looking for people with a particular diagnosis and finding out what they have in common genetically, the researchers can look forpeople who have genetic knockouts, and then examine their medical records to see how their missing genes affect their health. Its then possible to start piecing together the story of how certain genes affect physiology.

Finally, the researchers used the data to explore human history, using Y chromosome data from 753 Icelandic males. Based on knowledge about mutation rates, Y chromosomes can be used to trace the male lineage of human groups, establishing dates of events like migrations. This technique has also been used to work out when the common ancestor of all humans was alive. The maternal ancestor, known as Mitochondrial Eve, is thought to have lived 170,000 to 180,000 years ago, while the paternal ancestor had previously been estimated to have lived around 338,000 years ago.

See the original post here:

2,636 Icelandic genomes pinpoint risk for Alzheimers, other diseases

Advocate Health Care acquires land for medical offices in Huntley

HUNTLEY Advocate Health Care plans to build a new medical office building in Huntley, after the regional medical provider recently acquired six undeveloped acres near the Interstate 90 interchange, a property developer said.

Phillip Waters, vice president of development for Horizon Group, told the Northwest Herald that Horizon closed on the deal with Advocate earlier this winter.

Advocate plans to start construction on the new office building by the fall, as one of its competitors Centegra Health System continues to build a new hospital located on the north end of Huntley.

We are very excited to have them a part of the Huntley community, Waters said. Advocate is the largest health care provider in the state and a premier provider across the nation.

The six vacant acres are near the Huntley Corporate Park on the northwest corner of the I-90 interchange. Waters said he did not know Advocates specific plans for the area.

The health care provider paid fair market value for the vacant land, although Waters did not disclose the terms of the deal. An Advocate spokesperson did not return a request for comment Monday.

Advocates acquisition also follows Life Spine Inc.s recent move to Huntley. The medical device company in 2014 announced plans to move its corporate headquarters into a larger facility near the I-90 interchange.

Advocates medical office building would be located next to the Life Spines new headquarters, Waters said.

Read this article:

Advocate Health Care acquires land for medical offices in Huntley

Health Care Sector Update for 03/30/2015: ADMP,ICEL,BDSI

Top Health Care Stocks

JNJ +1.19%

PZE +1.35%

MRK +0.64%

ABT +0.92%

AMGN +0.82%

Health care stocks were higher in afternoon trade, with the NYSE Health Care Sector Index rising 1.1% and shares of health care companies in the S&P 500 up 0.9% as a group.

In company news, Adamis Pharmaceuticals Corp ( ADMP ) tumbled Monday after saying federal regulators have sent a Complete Response Letter to the drugmaker's new drug application for its prospective single-use epinephrine injection for acute allergic reaction.

According to the company, the U.S. Food and Drug Administration's questions only pertain to the dosing volume delivered by the syringe, including the levels contained in the drug's labeling claims and as required by the FDA.

No other safety or efficacy issues were raised by the agency, which is keeping the company's new drug application open during the review.

See the article here:

Health Care Sector Update for 03/30/2015: ADMP,ICEL,BDSI

ACMG Foundation announces inaugural recipient of Lovell Award

The ACMG Foundation for Genetic and Genomic Medicine announces the first recipient of the ACMG Foundation Carolyn Mills Lovell Award at the 2015 ACMG Annual Clinical Genetics Meeting in Salt Lake City, Utah: First award specifically for genetic counselors

Stephanie Harris, CGC was honored as the first recipient of the ACMG Foundation Carolyn Mills Lovell Award at the American College of Medical Genetics and Genomics (ACMG) 2015 Annual Clinical Genetics Meeting in Salt Lake City, Utah.

Ms. Harris was selected to receive the award for her poster presentation, "The Impact of Variant Reclassification on Hypertrophic Cardiomyopathy Research".

Ms. Harris completed her Masters of Science in Human Genetics and Genetic Counseling at Stanford University School of Medicine in Stanford, CA. and her Bachelor of Science in Biology at Bucknell University in Lewisburg, PA. She is currently a genetic counselor in Cardiovascular Genetics at Brigham and Women's Hospital in Boston, MA.

This award was made possible due to a generous donation by ACMG Medical Director David Flannery, MD, FAAP, FACMG to honor genetic counselor Carolyn Mills Lovell, MAT, MS, CGC. Dr. Flannery worked with Ms. Lovell for over 15 years while he was at the Medical College of Georgia (MCG) of Georgia Regents University, and wanted to recognize the contributions and accomplishments of genetic counselors through this award. This award includes a cash prize of $1000 and will be presented to one recipient annually through 2025.

"I wanted to help recognize genetic counselors who play a huge role in clinical genetic services and felt that this award would help with that and also honor Carolyn, who has always provided exemplary services to families, students and residents at MCG " said ACMG Medical Director David Flannery, MD, FAAP, FACMG.

ACMG Foundation President Bruce R. Korf, MD, PhD, FACMG added, "It is exciting to see the ACMG Foundation offer an award intended specifically for genetic counselors. Genetic counselors are integral members of the genetics care team and their role is expanding in this era of genomic medicine. I am very pleased to see the contribution of genetic counselors recognized through this award."

###

The ACMG Foundation for Genetic and Genomic Medicine, a 501(c)(3) nonprofit organization, is a community of supporters and contributors who understand the importance of medical genetics in healthcare. Established in 1992, the ACMG Foundation for Genetic and Genomic Medicine supports the American College of Medical Genetics and Genomics; mission to "translate genes into health" by raising funds to attract the next generation of medical geneticists and genetic counselors, to sponsor important research, to promote information about medical genetics, and much more.

To learn more about the important mission and projects of the ACMG Foundation for Genetic and Genomic Medicine and how you too can support this great cause, please visit http://www.acmgfoundation.org or contact us at acmgf@acmgfoundation.org or 301/718-2014.

Originally posted here:

ACMG Foundation announces inaugural recipient of Lovell Award

What is the best measure of depression severity in adolescents?

IMAGE:Journal of Child and Adolescent Psychopharmacology (JCAP), celebrating 25 years in 2015, is an authoritative peer-reviewed journal published 10 times a year in print and online. The Journal... view more

Credit: Mary Ann Liebert, Inc., publishers

New Rochelle, NY, March 30, 2015--At present the key symptom for diagnosing major depressive disorder (MDD) in adolescents is irritability. However a new study has found that the severity of anhedonia (the inability to gain pleasure from experiences that usually are enjoyable) rather than of irritability is associated with more severe MDD and worse clinical outcomes and suicide scores. Results of the study are published in Journal of Child and Adolescent Psychopharmacology (JCAP), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, and is available free on the JCAP website until April 30, 2015.

Vilma Gabbay, MD, and coauthors at Icahn School of Medicine at Mount Sinai and New York University Langone Medical Center (New York, NY), and Nathan S. Kline Institute for Psychiatric Research (Orangeburg, NY), used a quantitative approach to focus on symptoms of irritability and anhedonia simultaneously in 90 adolescents with MDD. Only anhedonia severity showed a significant correlation with the severity of overall outcomes, including illness severity, episode duration, and number of MDD episodes. In the article "Anhedonia, but not Irritability Is Associated with Illness Severity Outcomes in Adolescent Major Depression," the authors emphasize the importance of closely monitoring highly anhedonic depressed adolescents.

"This is a pivotal study of the critical aspects of adolescent depression," says Harold S. Koplewicz, MD, Editor-in-Chief of Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York. "The authors provide us with an insight that has significant implications for early intervention and effective treatment. Their work also reinforces the need for targeted studies of this disease in the adolescent population if we want to understand it and mitigate its harmful effects on youth."

###

About the Journal

Journal of Child and Adolescent Psychopharmacology (JCAP), celebrating 25 years in 2015, is an authoritative peer-reviewed journal published 10 times a year in print and online. The Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed on the JCAP website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cyberpsychology, Behavior, and Social Networking, Games for Health Journal, and Violence and Gender. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

See the article here:

What is the best measure of depression severity in adolescents?

Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological… – Video


Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological...
Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy. Alessandra Ricca et al (2015), Human...

By: KeSimpulan

Here is the original post:

Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological... - Video